Where to Inject Semaglutide and Tirzepatide: The Complete Patient Guide

Most GLP-1 telehealth providers ship a vial and a syringe with a one-line dosing instruction and almost no detail about where on the body the injection actually goes. The FDA prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro all approve the same three subcutaneous injection sites — the abdomen, the front of the thigh, and the back of the upper arm [1, 2, 3, 4]. Patient-reported soreness, ease of self- injection, and absorption profile vary meaningfully between them, but the labels themselves don't rank the three sites — they let you and your prescriber pick. This guide walks through the labeled anatomy with a body diagram, explains the rotation pattern that reduces lipohypertrophy and bruising, documents the injection depth and angle (which is the same for all four drugs), and covers the small technique details that make the difference between a comfortable injection and a sore one.

The three FDA-approved injection sites

The Wegovy [1], Ozempic [2], Zepbound [3], and Mounjaro [4] Instructions for Use documents all approve identical injection site options. There is no FDA-recommended site preference within them — the labels say only that the patient should rotate sites and pick from the three approved areas:

1. Abdomen. The most common site for self- injection. The label specifies anywhere on the abdomen except a 2-inch radius around the navel [1, 2, 3, 4]. The skin is loose and easy to pinch, the subcutaneous fat layer is generally thicker than the other sites, and self-injection is straightforward because the patient can easily see the injection site.
2. Front of thigh. The middle, mid-front of the thigh — not the inner thigh and not the lateral side. This is the second-most-common site. Slightly more patient-reported soreness than the abdomen because the quadriceps muscle sits directly under the subcutaneous fat layer and movement during walking can irritate the injection point for the first day or two.
3. Back of upper arm. The deltoid/triceps junction at the back of the upper arm. This site is generally not recommended for self-injectionbecause it's difficult for most patients to reach and to pinch the skin one-handed while inserting the needle. The label allows it but practical experience reserves it for patients who have a partner injecting them.

Why rotation matters

The most common patient mistake with GLP-1 injection technique is using the same spot week after week. Repeated injection into the same square inch of subcutaneous tissue causes a condition called lipohypertrophy — fatty nodules under the skin that absorb the drug unpredictably. Lipohypertrophy is a documented and well- characterized phenomenon in the insulin literature (Frid et al., Mayo Clinic Proceedings 2016 [5]) that translates directly to GLP-1 injections because the tissue and absorption physics are the same. The two clinical consequences:

1. Variable absorption. Drug injected into a lipohypertrophic nodule may absorb 25-50% slower than drug injected into normal tissue, producing inconsistent week- to-week effect. Patients often interpret this as “the medication stopped working” when in fact it's their injection site that changed, not the drug.
2. Reduced visibility. Lipohypertrophy nodules look and feel firm but not necessarily painful, so patients inject into them preferentially because the injection actually hurts less than fresh tissue. This makes the rotation problem self-reinforcing.

The recommended rotation pattern from both the Frid 2016 consensus [5] and the ADA Standards of Care [6] is to use a different square at least 1 inch away from the previous injection on each shot. A simple grid mental model: divide the abdomen into 8 quadrants (4 above the navel, 4 below) and inject into each one sequentially across 8 weeks before returning to the first. The same pattern works on the thighs.

Injection depth, angle, and technique

For all four GLP-1 drugs, the injection is subcutaneous, not intramuscular. That means into the layer of fat just under the skin, at a 90-degree angle (perpendicular) to the skin surface for most adults. Specific technique details from the FDA-approved IFU documents [1, 2, 3, 4]:

• Skin pinch: Pinch a 1-2 inch fold of skin and subcutaneous fat between thumb and forefinger to lift the tissue away from underlying muscle. This is the single most important technique detail — without the pinch, the needle can reach muscle in lean patients, which is more painful and changes absorption kinetics.
• Needle insertion: Insert at 90 degrees (straight in) for most patients. For very lean patients, a 45-degree angle is acceptable to avoid muscle.
• Inject slowly: Push the plunger over 5-10 seconds, not in a single fast push. This reduces the stinging sensation that some patients report from rapid injection.
• Hold the needle in place: After the plunger is fully depressed, hold the needle in the skin for an additional 5-10 seconds before withdrawing. This prevents drug leakage out of the injection site.
• Release the pinch and withdraw: Release the skin pinch and withdraw the needle in a single smooth motion. Apply light pressure with a clean cotton ball or gauze for 10 seconds. Do not rub the site — rubbing can cause bruising.

Brand pen vs compounded vial: what changes

The injection site rules and technique are identical for the brand-name pens and for compounded vial-and-syringe preparations. The mechanical differences are about the device, not the anatomy:

• Wegovy and Ozempic pens are pre-filled single-use auto-injectors that handle the needle and dose for the patient. The patient just selects the dose, places the pen against the skin, and presses the button. Manufacturer needle is short (4-5 mm) so even a moderate skin pinch reaches subcutaneous fat at every site [1, 2].
• Zepbound and Mounjaro pens work the same way — pre-filled, auto-injector, single-use, short needle [3, 4].
• Compounded vials are paired with a standard U-100 insulin syringe (typically 0.3 mL or 0.5 mL capacity) and the patient draws their own dose and injects manually. The needle is also short (typically 5/16" = 8 mm) but the patient is responsible for the full technique sequence above. For the unit-vs-mg dose calculation that comes up here, see our GLP-1 unit converter tool.

The compounded format requires more technique discipline because the patient performs every step manually, but the injection sites and the principles above don't change between formats.

Patient-reported tricks for less soreness

These are not in the FDA labels but they appear consistently in patient communities and are supported by the broader insulin injection technique literature [5]:

1. Cold or warm? Most patients report less stinging when the injection is given at room temperature rather than straight out of the refrigerator. Take the pen or vial out 15-30 minutes before injecting (within the room-temperature stability window — see our storage guide).
2. Pick a fresh site, not the “easy” spot. The site that hurts less today is often the one with early lipohypertrophy. Force yourself to rotate even when one spot feels noticeably easier.
3. Inject after a warm shower. Increased blood flow to surface tissue reduces the perceived sting.
4. Don't inject through clothing. Fabric fibers can be carried into the subcutaneous tissue and increase the chance of injection-site irritation.
5. Skip alcohol pad if you can't let it dry. Alcohol pads are routine but injecting through wet alcohol stings considerably more than injecting through dry skin. Wait 30 seconds for the alcohol to evaporate fully.

When to call your prescriber

Mild redness, mild bruising, and mild local soreness for 24-48 hours after a GLP-1 injection are common and not a cause for concern. Call your prescriber if any of the following happens:

• A firm lump under the skin that lasts more than 1-2 weeks (possible early lipohypertrophy or sterile abscess).
• Significant redness, warmth, or expanding swelling that worsens after the first 48 hours (possible infection).
• A nodule that becomes painful, red, and warm — call immediately, this can be a sterile abscess that requires medical evaluation.
• Repeated injections at the same site that have produced a visible lump — your prescriber should examine for lipohypertrophy and confirm a different rotation pattern.
• Any signs of a systemic allergic reaction (hives, swelling away from the injection site, breathing difficulty) — call 911 or go to the nearest emergency department.

Where the FDA labels are very clear (and where they leave you on your own)

The FDA-approved IFU documents are explicit about: the three approved sites, the requirement to rotate, the contraindication of injecting into a 2-inch radius around the navel, the subcutaneous (not intramuscular) route, and the prohibition on sharing needles between patients [1, 2, 3, 4]. The labels do not provide a recommended rotation pattern, do not specify how many days between repeating a site, and do not address site-specific differences in absorption or comfort. That gap is where third-party patient guides like this one — and the consensus literature [5, 6] — fill in the practical details.

Related research and tools

For the calculations that come up when you're drawing a compounded vial dose with a U-100 insulin syringe, see our GLP-1 unit converter. For the side-effect profile of each drug, see our GLP-1 side effects investigation. For pen vs compounded vial differences in operational practice, see our Wegovy pen vs compounded vial deep-dive. For the difference between semaglutide and tirzepatide themselves, see our tirzepatide vs semaglutide head-to-head.